How many insider trades does FilingIQ track for LNTH?

FilingIQ tracks 740 Form 4 insider transactions for LNTH (Lantheus Holdings, Inc.), covering filings from Jun 25, 2015 onwards. 18 of those were filed in the last 90 days.

Are LNTH insiders net buyers or net sellers?

Across the full Form 4 history for LNTH, 8 transactions (1%) were open-market purchases and 378 (51%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does LNTH insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is LNTH in?

Lantheus Holdings, Inc. (LNTH) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $4.97B.

LNTH insider trading

NasdaqGM Healthcare

Lantheus Holdings, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

740

Last 90 days

Buys / sells

1% / 51%

Market cap

$4.97B

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Company website: www.lantheus.com

LNTH insider activity at a glance

FilingIQ has scored 740 insider transactions for LNTH since Jun 25, 2015. The most recent filing in our index is dated Apr 17, 2026.

Across the full history, 8 open-market purchases and 378 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on LNTH insider trades is 58.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live LNTH trades on FilingIQ Raw filings on SEC EDGAR

Latest LNTH Form 4 filings

Marshall Robert J. Jr. CFO and Treasurer

S Mar 15, 2024

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding LNTH

Penn Capital Management Company, LLC

$15.40M · 1.5% of AUM

Ikarian Capital, LLC

$10.58M · 1.2% of AUM

Decheng Capital Management III (Cayman), LLC

$9.88M · 3.3% of AUM

Frequently asked

How many insider trades does FilingIQ track for LNTH?: FilingIQ tracks 740 Form 4 insider transactions for LNTH (Lantheus Holdings, Inc.), covering filings from Jun 25, 2015 onwards. 18 of those were filed in the last 90 days.
Are LNTH insiders net buyers or net sellers?: Across the full Form 4 history for LNTH, 8 transactions (1%) were open-market purchases and 378 (51%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does LNTH insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is LNTH in?: Lantheus Holdings, Inc. (LNTH) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $4.97B.

Methodology & sources

Every LNTH insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.